Home Protein & Antibody Therapeutics Developability Assessment

Developability Assessment – Achieve Low Volume, Data Driven Insights

Don't let limited sample availability stand in the way of developability assessments. With innovative technology, quantitatively analyze subvisible particles and proteins at high throughput with 5 μL – from early stage candidate selection to late stage formulation, identifying the best candidates to commercialize.

A Smarter Way to Screen for Drug Candidates

Identify Optimal Biologic Candidates:
Low Volume, Early Stage Developability with Aura PTx

Aura PTx is transforming the sample volume limited developability assessment stage by enabling subvisible particle characterization — the most
important critical quality attribute (CQA). Its high throughput, low volume modality enables high-level ranking decision making and reveals the most granular insights into particle formation and stability on a single platform.

Get the Full Picture of Protein Stability